Latham Advises Theramex on Licensing Agreement with ObsEva

Latham & Watkins has advised Theramex, a leading global pharmaceutical company specialising in women’s health, on its licensing agreement with ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, to commercialise and launch Linzagolix, an oral GnRH antagonist. The launch will be for global markets outside of the US, Canada, and Asia.

The Latham team was led by New York counsel Eliot Choy with London associate Oliver Mobasser.